UBS Group Raises Pfizer (NYSE:PFE) Price Target to $27.00

Pfizer (NYSE:PFE) had its price objective boosted by analysts at UBS Group from $25.00 to $27.00 in a report issued on Monday,Benzinga reports. The brokerage currently has a “neutral” rating on the biopharmaceutical company’s stock. UBS Group’s price target would indicate a potential downside of 1.19% from the company’s previous close.

Several other equities analysts have also weighed in on the stock. Bank of America dropped their price objective on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a research report on Thursday. BMO Capital Markets reaffirmed an “outperform” rating and set a $30.00 price target on shares of Pfizer in a research report on Monday, March 9th. Daiwa Securities Group lowered shares of Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 price target on the stock. in a research report on Thursday, February 12th. Argus raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $35.00 price target on the stock in a research report on Monday, March 2nd. Finally, Zacks Research raised shares of Pfizer from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 24th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, fourteen have assigned a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $28.24.

Pfizer Stock Performance

Shares of PFE traded up $0.40 during trading hours on Monday, hitting $27.32. The company had a trading volume of 44,069,163 shares, compared to its average volume of 44,758,160. The firm has a market cap of $155.37 billion, a price-to-earnings ratio of 20.09 and a beta of 0.43. The business has a fifty day moving average of $27.20 and a 200-day moving average of $25.96. Pfizer has a 12 month low of $21.87 and a 12 month high of $28.75. The company has a quick ratio of 0.87, a current ratio of 1.16 and a debt-to-equity ratio of 0.71.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.57 by $0.09. The company had revenue of $17.56 billion for the quarter, compared to analyst estimates of $16.93 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The company’s revenue was down 1.2% on a year-over-year basis. During the same period in the prior year, the firm earned $0.63 earnings per share. Equities analysts anticipate that Pfizer will post 2.95 EPS for the current fiscal year.

Hedge Funds Weigh In On Pfizer

A number of hedge funds have recently bought and sold shares of the business. Horizon Financial Services LLC grew its stake in Pfizer by 174.8% during the fourth quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 645 shares in the last quarter. Godfrey Financial Associates Inc. acquired a new stake in Pfizer during the fourth quarter worth about $26,000. YANKCOM Partnership acquired a new stake in Pfizer during the fourth quarter worth about $28,000. Grey Fox Wealth Advisors LLC acquired a new stake in Pfizer during the third quarter worth about $29,000. Finally, HFM Investment Advisors LLC grew its stake in Pfizer by 61.0% during the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 427 shares in the last quarter. 68.36% of the stock is owned by institutional investors.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.